Lefamulin (Xenleta) for Community Acquired Bacterial Pneumonia
January 21, 2020
Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
SUBSCRIBE: Print / Digital / eNewsletter
Lefamulin was approved by the FDA in August 2019 for the treatment of CABP.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
